John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.
Analyzing Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 Administration
November 20th 2023A study demonstrates the microbiome changes and how restoration of the gut flora is warranted when patients are dealing with recurrent bouts of the health care-associated infection.
Read More
This Week's Biggest Infectious Disease Stories
November 17th 2023This week we covered antibiotic de-escalation, the approved fecal microbiota options for prevention of recurrent Clostridioides difficile, the CDC's recommendations for HCV testing in the pediatric populations, and examining pragmatic approaches to skin and soft tissue Infections.
Read More
What Specialties are Using Live Biotherapeutic Products?
November 13th 2023With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.
Read More
Changing the Antibiotic Reimbursement Model to Encourage Drug Development Proliferation
November 12th 2023Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.
Read More
In this week's news, CDC sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody; a clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices; and antidepressants were associated with a greater risk of Clostridioides difficile infection (CDI).
Read More
Moderna Begins Phase 3 Trial for its Influenza-COVID-19 Vaccine
October 26th 2023The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.
Read More
This Week's Infectious Disease News
October 22nd 2023This week's news included a new study that showed the association with Epstein-Barr virus reactivation and sets the need for an antiviral clinical trial with cardiopulmonary exercise testing as an endpoint; a clinician weighs in on the limited use of novel, gram-negative antibiotics; and the discussion around increasing hepatitis C testing for the pediatric population.
Read More
2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV
October 21st 2023The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.
Read More